# FEMASYS (FEMY) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/FEMY
## Company Profile
- Ticker: FEMY
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech, Women's Health
## Stock Data
- Close: 3.06 USD
- Market cap: 22423061.7118 USD
- Last updated: 2026-09-03
## Business Overview
Femasys is a women’s health medical technology company focused on fertility and reproductive-health products. Its business is centered on procedures and devices that address unmet needs in women’s health.
## Why The Stock Is Moving

As of Sep 3, 2026, FEMY closed down 1.29% at $3.06. No new same-company headline was identified in the current news window.

## Geographic Base

Femasys is headquartered in the United States and listed on NASDAQ. It sits in women’s-health medtech rather than biotechnology.

## Business Model

The company depends on product adoption, physician acceptance, and regulatory or commercial milestones. Investors watch launch execution, reimbursement, and the pace of market penetration.

## Landscape Position

Femasys occupies a women’s-health device niche within healthcare innovation. It is not biotech proper, but its growth still depends on product adoption and clinical credibility.

## Future Catalysts

- Femasys’s catalysts are FemBloc commercialization and women’s-health product development, where adoption and regulatory progress matter most. The company needs to show the platform can translate into real clinical use.

## Recent News
- 2026-08-26 13:00 EST — [Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations](https://biopharmsignal.com/news/FEMY/femasys-partners-with-unc-health-to-introduce-its-femaseed-fertility-portfolio-a-9ab427cc) — Source: FEMASYS
- 2026-08-19 13:00 EST — [Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®](https://biopharmsignal.com/news/FEMY/femasys-announces-fda-approval-of-modular-pma-submission-approach-for-fembloc-ca44fc30) — Source: FEMASYS
- 2026-08-14 20:05 EST — [Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update](https://biopharmsignal.com/news/FEMY/femasys-announces-financial-results-for-quarter-ended-june-30-2026-and-provides--48093ff5) — Source: FEMASYS
- 2026-08-12 13:00 EST — [Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents](https://biopharmsignal.com/news/FEMY/femasys-strengthens-and-extends-global-patent-protection-for-fembloc-with-first--d1729517) — Source: FEMASYS
- 2026-08-07 13:25 EST — [Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million](https://biopharmsignal.com/news/FEMY/femasys-secures-30-million-private-placement-with-potential-proceeds-of-up-to-90-9edc7de9) — Source: FEMASYS